News AnnouncementNovember 15, 2010
The development of new drugs to treat and prevent HIV/AIDS depends on understanding the basic biology of how the virus infects human cells. For 25 years, researchers supported primarily by NIH’s National Institute of General Medical Sciences (NIGMS) have been generating the structures of key viral proteins, revealing important insights into the virus’s mechanisms and, more importantly, its Achilles’ heels.
This NIGMS program is one element of NIH’s broader HIV/AIDS research effort.
Initially, the program’s main objectives were to determine the structures of virally encoded molecules and to test the relatively new idea that such structural knowledge could be used to design new drugs. The 30 research groups involved in the effort were highly successful. They revealed new insights into how viral proteins function during the infectious cycle and how the virus can develop drug resistance. The work also helped to validate the structure-based drug design approach. An important example is Viracept (nelfinavir), which is widely used to inhibit the action of the viral protein HIV protease and, as a result, stop the virus from infecting more cells.
Now, the program centers on a new challenge: detailing HIV-host events during all stages of the virus’s life cycle. The mission, which pushes the state of the art in structural biology and HIV research, is to visualize how the different components interact and point to new approaches for disrupting those interactions.
Specific areas of interest include:
Researchers will discuss the exciting progress in these and related areas during the 25th annual meeting on HIV/AIDS-related structural biology. The meeting, which is free to attend, will be held on the NIH campus in Bethesda, Md., from March 28 to March 30, 2011.
If you are a reporter and would like to learn more about NIGMS’ $57 million program on the basic biology of HIV (including the structural biology effort), interview one of its scientists or attend the 2011 meeting, please contact the NIGMS Office of Communications and Public Liaison at 301-496-7301 or email@example.com.
This page last reviewed on
8/9/2018 5:46 PM
Connect With Us: